




# EXHIBIT 1

FIG. 54




# EXHIBIT 2

FIG. 55 A




# EXHIBIT 3

FIG. 55 B



# EXHIBIT 4

FIG. 57





# EXHIBIT 5






FIGURE 65

# EXHIBIT 6

A)



B)





Figure 66

# EXHIBIT 7

A)



B)





Figure 67

# EXHIBIT 8

A)



B)





Figure 68



# EXHIBIT 9

A)



B)




Figure 69

# EXHIBIT 10





Figure 70


# EXHIBIT 11

## PSCA 3C5 MAb Localizes within LAPC9AD Xenograft Tissue

3C5 Treated



mIgG Treated



*Figure 71*

# EXHIBIT 12

# 3C5 Anti-PSCA MAb is Localized to Established LAPC-9 Tumors





Figure 72



# EXHIBIT 13

# SPECIFIC TARGETING OF THE 1G8 ANTI-PSCA MAb TO ESTABLISHED LAPC-9 TUMORS



**Method:** Mice bearing established LAPC-9 tumors (>100 mm<sup>3</sup>) were injected with either mIgG or the anti-PSCA MAb 1G8. Tumors were harvested a week later and made into protein lysates for Western analysis.

Figure 73